Literature DB >> 25672935

Decreased expression of SCUBE2 is associated with progression and prognosis in colorectal cancer.

Qi Song1, Chuanwei Li1, Xiaodong Feng1, Ailian Yu2, Huamei Tang3, Zhihai Peng4, Xuechun Wang1.   

Abstract

Signal peptide-CUB-epidermal growth factor-like domain-containing protein 2 (SCUBE2), a member of the SCUBE protein family, is a secreted and membrane-associated multi-domain glycoprotein. SCUBE2 is known as a novel tumor suppressor and a useful prognostic marker in breast cancer. In the present study, we investigated the expression (including mRNA and protein levels) of SCUBE2 in colorectal cancer (CRC) and adjacent normal tissues, using quantitative real-time PCR, western blot analysis and immunohistochemistry on a tissue microarray. Upregulation of SCUBE2 was achieved by transient transfection in RKO cell lines, and the effects of SCUBE2 on tumor proliferation, invasion, migration and apoptosis were evaluated by a series of functional experiments. The results indicated that SCUBE2 expression was decreased at the transcriptional and translational levels in CRC tissues and significantly associated with clinical stage, the depth of tumor invasion, lymph‑node metastasis, distant metastasis and histological grade. Patients with SCUBE2‑positive tumors had a lower recurrence rate and better survival than patients with SCUBE2-negative tumors. Moreover, upregulation of SCUBE2 had a limited effect on cell apoptosis but significantly inhibited tumor cell proliferation, migration and invasion in vitro. In conclusion, SCUBE2 plays an important role in suppressing CRC progression and prognosis. Our findings suggested that SCUBE2 may serve as a novel tumor suppressor and a potential therapeutic target for CRC patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25672935     DOI: 10.3892/or.2015.3790

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Estrogen receptor-positive breast cancer survival prediction and analysis of resistance-related genes introduction.

Authors:  Chen Shuai; Fengyan Yuan; Yu Liu; Chengchen Wang; Jiansong Wang; Hongye He
Journal:  PeerJ       Date:  2021-10-26       Impact factor: 2.984

2.  Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients.

Authors:  Areej Fatima; Fomaz Tariq; Muhammad Faraz Arshad Malik; Muhammad Qasim; Farhan Haq
Journal:  J Breast Cancer       Date:  2017-09-22       Impact factor: 3.588

3.  Candidate Predisposition Variants in Kaposi Sarcoma as Detected by Whole-Genome Sequencing.

Authors:  Sanni J Rinne; Lauri J Sipilä; Päivi Sulo; Emmanuelle Jouanguy; Vivien Béziat; Laurent Abel; Jean-Laurent Casanova; Nima Parvaneh; Kamran Balighi; Emma Guttman-Yassky; Ronit Sarid; Lauri A Aaltonen; Mervi Aavikko
Journal:  Open Forum Infect Dis       Date:  2019-07-17       Impact factor: 3.835

4.  A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer.

Authors:  Jim Kallarackal; Florian Burger; Stefano Bianco; Alessandro Romualdi; Martina Schad
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

Review 5.  Hedgehog Signal and Genetic Disorders.

Authors:  Noriaki Sasai; Michinori Toriyama; Toru Kondo
Journal:  Front Genet       Date:  2019-11-08       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.